Does responsive closed-loop stimulation of the centromedian thalamus safely and effectively reduce generalized tonic-clonic seizures in patients with drug-resistant idiopathic generalized epilepsy?
Can eslicarbazepine acetate prevent the development of post-stroke epilepsy in patients at high risk after acute stroke?
BIA-2093-213
Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial
Lancet Neurology · 2026
Bottom Line: Eslicarbazepine acetate did not significantly reduce the composite endpoint of first unprovoked seizure, death, or treatment discontinuation compared to placebo in post-stroke patients (28% vs 37%, OR 0.66, p=0.37). The trial was underpowered due to slow recruitment and COVID-19 disruptions but demonstrates the feasibility of conducting antiepileptogenesis trials.